Log in to save to my catalogue

PENSA study, results of a 12‐month personalized intensive multimodal lifestyle intervention compleme...

PENSA study, results of a 12‐month personalized intensive multimodal lifestyle intervention compleme...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11714784

PENSA study, results of a 12‐month personalized intensive multimodal lifestyle intervention complemented with epigallocatechin gallate (EGCG) to prevent cognitive decline in APOE‐ ɛ4 carriers with Subjective Cognitive Decline: a randomized, double‐blinded clinical trial

About this item

Full title

PENSA study, results of a 12‐month personalized intensive multimodal lifestyle intervention complemented with epigallocatechin gallate (EGCG) to prevent cognitive decline in APOE‐ ɛ4 carriers with Subjective Cognitive Decline: a randomized, double‐blinded clinical trial

Publisher

Hoboken: John Wiley and Sons Inc

Journal title

Alzheimer's & dementia, 2024-12, Vol.20 (S7), p.n/a

Language

English

Formats

Publication information

Publisher

Hoboken: John Wiley and Sons Inc

Subjects

Subjects and topics

More information

Scope and Contents

Contents

Background
Lifestyle interventions targeting multiple Alzheimer’s disease (AD) risk factors are effective strategies to prevent cognitive decline. Emerging evidence suggests synergistic effects between various intervention components, including lifestyle modifications, supplements, and pharmacological approaches. The PENSA study, part of the Wor...

Alternative Titles

Full title

PENSA study, results of a 12‐month personalized intensive multimodal lifestyle intervention complemented with epigallocatechin gallate (EGCG) to prevent cognitive decline in APOE‐ ɛ4 carriers with Subjective Cognitive Decline: a randomized, double‐blinded clinical trial

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11714784

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11714784

Other Identifiers

ISSN

1552-5260

E-ISSN

1552-5279

DOI

10.1002/alz.088694

How to access this item